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Rationale: Limited data on sex differences in advanced COPD are
available.
Objectives: To compare male and female emphysema patients with
severe disease.
Methods: One thousand fifty-three patients (38.8% female) evalu-
ated for lung volume reduction surgery as part of the National
Emphysema Treatment Trial were analyzed.
Measurements and Main Results: Detailed clinical, physiological, and
radiological assessment, including quantitation of emphysema se-
verity and distribution from helical chest computed tomography,
was completed. In a subgroup (n  101), airway size and thickness
was determined by histological analyses of resected tissue. Women
were younger and exhibited a lower bodymass index (BMI), shorter
smoking history, less severe airflow obstruction, lower DLCO and
arterial PO2, higher arterial PCO2, shorter six-minute walk distance,
and lower maximal wattage during oxygen-supplemented cycle
ergometry. For a given FEV1% predicted, age, number of pack-
years, and proportion of emphysema, women experienced greater
dyspnea, higher modified BODE, more depression, lower SF-36
mental component score, and lower quality of well-being. Overall
emphysema was less severe in women, with the difference from men
most evident in the outer peel of the lung. Females had thicker small
airway walls relative to luminal perimeters.
Conclusions: In patients with severe COPD, women, relative to men,
exhibit anatomically smaller airway lumens with disproportionately
thicker airway walls, and emphysema that is less extensive and
characterized by smaller hole size and less peripheral involvement.
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Sex differences in chronic obstructive pulmonary disease
are increasingly recognized.
What This Study Adds to the Field
In patients with severe COPD, women, relative to men,
exhibit anatomically smaller airway lumens with dispropor-
tionately thicker airway walls, and emphysema that is less
extensive and characterized by smaller hole size and less
peripheral involvement.
Keywords: chronic obstructive pulmonary disease; emphysema; computed
tomography; pulmonary function; gender
The prevalence and mortality of chronic obstructive pulmonary
disease (COPD) in female smokers is rapidly increasing (1).
Female smokers are more likely than men to report respiratory
symptoms (2–4) and exhibit greater baseline airway respon-
siveness to methacholine (5). Indirect evidence suggests that
women may be more predisposed to develop smoking-induced
lung function impairment (4, 6, 7) and experience greater mortal-
ity (8). Despite these compelling data, COPD continues to be
underdiagnosed in women (9), and research into sex differences
in advanced COPD remains limited (4, 10, 11). Using carefully
characterized patients from theNational EmphysemaTreatment
Trial (NETT), we hypothesized that differences in disease ex-
pression in severe emphysema would be identified between
males and females. Specifically, we sought to examine differences
in the symptomatic, physiological, radiological, and histological
expression of emphysema.
METHODS
Patient Selection
The study group consisted of 1,053 patients randomized at 17 NETT
clinics (12) in whom baseline high resolution computed chest tomo-
graphs (HRCT) were available for analysis at the Imaging Analysis
Center of the University of Iowa (see below). The design and methods
of the trial have been detailed previously (12, 13); major enrollment
criteria are enumerated in the online supplement.
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Clinical Assessment
Demographic data and medical history were collected using standard-
ized instruments. Health status was assessed using general and disease-
specific instruments. Dyspnea was quantified using the University of
California, San Diego Shortness of Breath Questionnaire (UCSD
SOBQ) (14). Depression was assessed using the Beck Depression In-
ventory (15).
Physiological Testing
Patients underwent spirometry before and after albuterol administra-
tion, while plethysmographic lung volumes were measured after albut-
erol administration. Diffusing capacity and arterial blood gases were
also measured. The protocol for 6-minute walk testing (6MWT) has
been described (16). Maximal exercise capacity was measured using a
cycle ergometer. A multidimensional index, the BODE, was modified
using previously described methodology (mBODE) (17).
Diagnostic Imaging Studies
Emphysema severity and distribution was determined from chest com-
puted tomography (CT) scans obtained at full inspiration. After seg-
menting and dividing the lung according to previously described proto-
cols (18), images were analyzed using custom-built software, the
Pulmonary Analysis Software Suite (PASS). The density histogram
was plotted, with values less than 950 HU corresponding to severe
emphysema and regions with values of910 HU and850 HU roughly
equating to moderate and mild emphysema, respectively. The alpha
value (inverse slope) was determined from the log–log relationship of
hole size versus number of holes (19). Lungs with greater proportions
of small lesions have a steep negative slope and a large alpha.
Histological Assessment
Lung tissue was available for analysis in 101 subjects from five centers
(Baylor, Colorado,Michigan, Pittsburgh, and Temple). Previous reports
have described the methods used to process the tissue and to estimate
airways remodeling and luminal occlusion by inflammatory exudates
containing mucus (20). We examined cross sections of airways  2 mm
in diameter. Maximal lumen area was calculated (18, 21). Wall thickness
included the area between the epithelial luminal surface and the connec-
tive tissue at the outer limit of the adventitia. The fractional areas (Vv)
taken up by epithelium, lamina propria, the smooth muscle itself, and
the adventitia were also measured. The ratio of tissue area to basement
membrane length was used to express the volume to surface (V/S) ratio
or thickness of the airway wall and its compartments.
Statistical Analysis
Continuous data were compared using t tests.Multivariate linear regres-
sion models were used to assess the relationships between sex and
dependent variables of FEV1% predicted, mBODE, dyspnea, depres-
sion, health status scores, whole-lung emphysema, and whole-lung
alpha. Potential confounders included age, number of pack-years,
whole-lung emphysema proportions, and FEV1% predicted (con-
founder excluded when it was the dependent variable in the model).
mBODE or inspiratory capacity (IC)/TLC were also explored as con-
founders when appropriate. All sex comparisons of airway wall and its
compartments were performed using a mixed hierarchical model, which
accounted for the clustering of airway analysis within subjects (Proc
Mixed, version 9.1; SAS, Carey, NC).
RESULTS
Patient Demographics and Baseline Physiology
Compared with males, female subjects were slightly younger,
had a slightly lower mean BodyMass Index (BMI), and reported
significantly shorter smoking histories and an older age at the
time of smoking onset (Table 1). Women exhibited slightly less
severe airflow obstruction but a similar TLC, slightly lower dif-
fusing capacity (DlCO), IC/TLC, PaO2, and higher PaCO2. The
difference in PaO2 persisted when adjusted for differences in
PaCO2 (difference 2.21 mm Hg; 95% confidence interval [95%
CI],3.44,0.98;P 0.0004). The 6MWTandmaximal exercise
capacity were lower in women. Men exhibited slightly lower
1-antitrypsin levels than women (Table 1), although the distri-
bution of 1 genotypes was not different (P  0.44, data not
shown). In the cohort there were only 16 patients felt to be
1-deficient; in this group, only two were females.
After adjusting for age, pack-years of smoking, and whole-
lung emphysema proportion, women showed a higher prebron-
chodilator FEV1% predicted than men (mean FEV1% predicted
2.98% greater; 95% CI, 2.19, 3.78; P  0.0001). Although the
results were not statistically confirmed when predicted values
of Hankinson and coworkers (22) were substituted for those of
Crapo and colleagues (23–25), the direction remained suggestive
(mean FEV1% predicted 0.69% greater; 95% CI, 0.14, 1.51;
P  0.10). All interactions involving sex and other predictors
in themodel were investigated; nonewere found to be significant.
Results were similar when postbronchodilator FEV1 was exam-
ined (data not shown). Lower DlCO in females remained signifi-
cant (2.79% pred; 95% CI, 3.99, 1.58) after adjustment
for whole lung emphysema proportion, age, and pack-years of
smoking.
Breathlessness, Depression, and Health Status
Female patients noted greater breathlessness (UCSD SOBQ)
and depression (Beck total score), and lower SF-36 mental com-
ponent score (MCS) (Table 1). Increased breathlessness in
women (average adjusted UCSD SOBQ score 5.03 higher; 95%
CI, 2.57–7.49) remained significant (P  0.0001) after adjusting
for age, FEV1% predicted, whole-lung emphysema proportion,
and pack-years (Table 2). Results were similar when postbron-
chodilator FEV1 was used in the models (data not shown), al-
though they were less evident when the IC/TLC was included
in the model (see Table E1 in the online supplement).
In separate multivariate models predicting total Beck score
(Table 2) and SF-36 MCS (Table 2), significant interactions be-
tween age and sex were found after adjusting for FEV1% pre-
dicted, whole-lung emphysema proportion, and pack-years.
These sex interactions remained when the FEV1 was replaced
by the IC/TLC score or the mBODE (Tables E1 and E2). Based
on these interaction analyses, our data suggest that women under
the age of 79.2 years tended to have a higher total Beck score
than men, but as age increased, the total Beck score tended
to decrease more rapidly in women than in men (Figure 1A).
Similarly, women under the age of 73.5 years tended to have a
lower SF-36 MCS than men of the same age, with the disparity
between sexes decreasing with age (Figure 1B). These strong
sex interactions remained evident after adjustment for mBODE
scores (Figure E1). No other interactions with sex were found
to be significant in Table 2.
Few differences were noted between sexes in health status,
as assessed by the SF-36 physical component score or the SGRQ,
in either univariate ormultivariate analyses (Table 2). In univari-
ate analysis, QWB was marginally lower in women than men
(P  0.05). In the multivariate setting (Table 2), the statistical
significance of the association of QWBwith female sex increased
after adjusting for confounders (on average females lower by
0.02; 95% CI, 0.003, 0.036 lower; P  0.02). Results were
quantitatively similar using both sets of predicted values for
FEV1. When postbronchodilator FEV1 was used in modeling the
association of QWB and sex, it became marginally significant
(0.001; 95% CI, 0.00001, 0.0002; P  0.05).
Radiographic Assessment of Emphysema Proportion
and Distribution
The proportion of whole-lung emphysema in women was lower
using a threshold that identifies moderate emphysema (910 HU,
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TABLE 1. BASELINE CHARACTERISTICS FOR PATIENTS WITH SEVERE EMPHYSEMA
Men Women
(n  644) (n  409)
Parameter Mean (SD) Mean (SD) P Value
Demographics/Laboratory
Age, yr 67.0 (6.2) 65.4 (6.1) 0.0001
BMI, kg/m2 25.0 (3.7) 24.4 (4.2) 0.007
Pack-years 71.1 (32.3) 54.8 (24.2) 0.0001
Age at onset of smoking habit, yr 16.0 (3.7) 17.7 (3.9)  0.0001
1-antitrypsin, mg/dl 152.4 (36.0) 163.0 (37.5)  0.0001
Physiology*
Pre BD FEV1, ppd 22.7 (6.4) 25.6 (6.2) 0.0001
Post BD FEV1, ppd 25.9 (7.1) 29.0 (6.6)  0.0001
(Post BD FEV1-Pre BD FEV1)/Pre BD FEV1 0.15 (0.13) 0.15 (0.14) 0.50
Post BD FEV1ppd –Pre BD FEV1ppd 3.23 (2.80) 3.46 (3.15) 0.22
TLC, ppd 128.3 (13.9) 129.3 (14.8) 0.28
DLCO, ppd 29.3 (10.0) 27.2 (9.0) 0.0005
6MWT, ft 1185.5 (322.5) 1076.7 (291.7) 0.0001
Maximum load, watts 43.0 (22.4) 26.2 (14.4)  0.0001
PaO2, mm Hg 65.8 (10.13) 62.8 (10.30)  0.0001
PaCO2, mm Hg 42.2 (5.17) 43.3 (5.40) 0.0008
IC/TLC 0.23 (0.06) 0.21 (0.06)  0.0001
Symptoms and Health Status
UCSD SOBQ 64.0 (18.9) 67.4 (18.8) 0.005
SF-36 PCS 28.4 (7.7) 28.5 (7.6) 0.92
SF-36 MCS 53.1 (10.8) 51.6 (10.8) 0.03
QWB 0.542 (0.120) 0.527 (0.127) 0.05
SGRQ overall score 56.4 (13.0) 56.2 (13.2) 0.79
Beck Total Score 8.7 (5.59) 10.4 (6.90) 0.0001
Multidimensional Index
mBODE 5.27 (1.59) 5.72 (1.59)  0.0001
Imaging
Whole lung emphysema proportion
950 HU threshold 0.16 (0.11) 0.15 (0.11) 0.07
910 HU threshold 0.44 (0.12) 0.41 (0.12) 0.0001
Alpha
950 HU threshold 1.02 (0.20) 1.06 (0.24) 0.001
910 HU threshold 0.71 (0.12) 0.74 (0.14) 0.01
Whole lung peel emphysema proportion at 950 HU 0.123 (0.091) 0.105 (0.086) 0.002
Whole lung core emphysema proportion at 950 HU 0.207 (0.128) 0.207 (0.138) 0.93
Definition of abbreviations: 6MWT  six minute walk test; BD  bronchodilator; BMI  body mass index; DLCO  diffusing capacity
for carbon monoxide; HU  Hounsfield Unit; IC inspiratory capacity; maximum load maximal exercise capacity measured on cycle
ergometry while breathing 30% FIO2; mBODE  modified BODE; MCS  mental component scale; PaO2  room air resting PaO2 in
mm Hg; PaCO2  room air resting PaCO2 in mm Hg; ppd percent predicted; PCS  physical component scale; QWB  quality of well-
being; SF-36  Short form 36 health survey; SGRQ  St. George’s Respiratory Questionnaire; UCSD SOBQ  University of California,
San Diego Shortness of Breath Questionnaire.
*Physiologic predicted values of Crapo and coworkers (23–25).
P  0.0001), and marginally lower using a threshold for severe
emphysema (950 HU, P  0.07) (Table 1). These associations
were maintained in multivariate models (Table 3) (on average
3% less moderate emphysema; 95% CI, 1.4–4.6% less; P 
0.0002, on average 16.4% less severe emphysema; 95% CI, 0.2–
30.5% less; P  0.02). Postbronchodilator FEV1 was significant
when included in the model identifying severe emphysema
(950 HU) (0.001; 95% CI,0.002,0.0002, P 0.01), while
other differences were unchanged. These results remained quali-
tatively similar when the FEV1 was replaced by the IC/TLC
(Table E3) and the mBODE (Table E4). Similarly, women ex-
hibited significantly higher whole-lung alpha value using either
emphysema threshold (Tables 1 and 3). No significant interac-
tions of other covariates with sex were found in any of the
multivariate models in Table 3.When the analyses were adjusted
for IC/TLC (Table E3) and mBODE (Table E4) in place of
FEV1, the direction of these differences was similar.
Emphysema distribution also differed between sexes (Table 1).
Women showed a similar proportion of emphysema in the core
of the lung (P  0.93) but a lower proportion in the peel (P 
0.002). Results were quantitatively similar using both sets of
predicted values for FEV1.
Histological Assessment
The small airways of the female lung had a reduced basement
membrane length (PI) compared with male lungs, but only mar-
ginally lower total wall area (Table 4). This disparity resulted
in clear sex differences (P  0.05) in estimates of thickness
obtained from the ratio of wall area/PI for the total wall and its
epithelial and adventitial compartments.
DISCUSSION
This retrospective analysis of a large, prospectively studied co-
hort of patients with severe COPD enrolled in a clinical trial of
lung volume reduction surgery documents sex-specific disparities
in symptom severity, health status, and distribution of pathologic
changes assessed using both radiological and histological tech-
niques. For a given age, FEV1% predicted, smoking history, and
proportion of emphysema, women experienced greater dyspnea,
246 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 176 2007
TABLE 2. MULTIVARIATE LINEAR REGRESSION MODELS PREDICTING THE MBODE, DYSPNEA,
BECK DEPRESSION SCORES, AND HEALTH STATUS IN PATIENTS WITH SEVERE EMPHYSEMA
(N  1,053)
Parameter 95% Confidence
Estimate Interval P Value
Modified BODE
Intercept 5.69 (4.47, 6.90)  0.0001
Age 0.02 (0.04, 0.003) 0.02
Whole lung emphysema proportion, 910 HU 0.01 (0.005, 0.02) 0.002
Pack-years 0.002 (0.001, 0.006) 0.19
Female sex 0.42 (0.20, 0.64) 0.0002
UCSD SOBQ
Intercept 98.22 (84.8, 111.68)  0.0001
FEV1, % predicted 0.59 (0.77, 0.41)  0.0001
Age, yr 0.31 (0.50, 0.13) 0.001
Whole lung emphysema proportion, 910 HU 5.57 (14.8, 3.68) 0.24
Pack-years 0.036 (0.001, 0.07) 0.06
Female sex 5.03 (2.57, 7.49)  0.0001
Beck Total score
Intercept 12.56 (7.18, 17.9)  0.0001
FEV1, % predicted 0.05 (0.11, 0.01) 0.09
Age, yr 0.07 (0.15, 0.002) 0.06
Whole lung emphysema proportion, 910 HU 0.40 (2.63, 3.43) 0.80
Pack-years 0.03 (0.02, 0.04)  0.0001
Female sex 11.09 (3.02, 19.2) 0.007
Age, yr · female sex 0.14 (0.26, 0.01) 0.03
SF-36 Physical component score
Intercept 12.82 (7.27, 18.4)  0.0001
FEV1, % predicted 0.06 (0.01, 0.14) 0.11
Age, yr 0.20 (0.12, 0.28)  0.0001
Whole lung emphysema proportion, 910 HU 2.49 (1.33, 6.30) 0.20
Pack-years 0.004 (0.02, 0.01) 0.64
Female sex 0.20 (0.82, 1.21) 0.70
SF-36 Mental component score
Intercept 52.52 (42.9, 62.1)  0.0001
FEV1, % predicted 0.03 (0.07, 0.14) 0.56
Age, yr 0.02 (0.12, 0.15) 0.80
Whole lung emphysema proportion, 910 HU 2.76 (2.64, 8.16) 0.32
Pack-years 0.04 (0.06, 0.01) 0.002
Female sex 19.1 (33.50, 4.74) 0.009
Age, yr · female sex 0.26 (0.04, 0.48) 0.02
QWB Score
Intercept 0.394 (0.304, 0.483)  0.0001
FEV1, % predicted 0.0008 (0.0004, 0.002) 0.17
Age, yr 0.002 (0.0007, 0.003) 0.002
Whole lung emphysema proportion, 910 HU 0.056 (0.005, 0.117) 0.07
Pack-years 0.0004 (0.0006, 0.001) 0.003
Female sex -0.02 (0.036, 0.003) 0.02
SGRQ Total Score
Intercept 90.61 (81.31, 99.91)  0.0001
FEV1, % predicted 0.24 (0.36, 0.11) 0.0002
Age, yr 0.41 (0.54, 0.28)  0.0001
Whole lung emphysema proportion, 910 HU 7.69 (14.09, 1.30) 0.02
Pack-years 0.03 (0.0005, 0.05) 0.05
Female sex 0.02 (1.68, 1.72) 0.98
Definition of abbreviations: HU  Hounsfield Unit; QWB  quality of well-being; SF-36  Short form 36 health survey; UCSD
SOBQ University of California, San Diego Shortness of Breath Questionnaire.
higher mBODE scores, higher depression scores, a lower SF-36
MCS, and a lower quality of well-being than men. Women also
showed less severe overall emphysema than men, particularly
in the lung peel, and smaller emphysema hole size, even with
adjustment for FEV1% predicted, age, and smoking history. The
small ( 2mmdiameter) airways ofwomen had relatively thicker
walls and disproportionately reduced airway lumens. By simulta-
neously correlating symptoms with carefully standardized physi-
ological, radiological, and histological data, these results for the
first time unite several previously separate lines of investigation
in women’s health and COPD.
These data showing greater breathlessness in women relative
to men at similar degrees of airflow obstruction and emphysema
severity are important because they imply that sex-specific
anatomic differences must be considered in models of COPD
pathogenesis. Interestingly, this difference was less evident after
adjustment in IC/TLC, suggesting that part of this difference
may relate to differences in lung volume. Our data agree with
population-based studies in whichwomen reported greater respi-
ratory symptoms (3, 26–31), with twomultinational studies based
on physician-reported COPD, in which women were more likely
to report severe dyspnea (2, 32), and with two case-control
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Figure 1. (A ) Relationship of total Beck score (y axis) to age (x axis) when FEV1% predicted, whole-lung % emphysema proportion, and pack-
years are held constant. An interaction of age and sex is evident, and is significant (P  0.03). (B ) Relationship of SF-36 Mental Component Score
(y axis) to age (x axis) when FEV1% predicted, whole-lung % emphysema proportion, and pack-years are held constant. An interaction of age and
sex is evident and is significant (P  0.02).
studies (33, 34). The magnitude of difference in breathlessness
in multivariate modeling in our data was above the level felt to
be a minimal clinically important difference with this instrument
(35). When the dyspnea score was incorporated in a validated
TABLE 3. MULTIVARIATE MODELS PREDICTING EMPHYSEMA PROPORTION IN PATIENTS WITH
SEVERE EMPHYSEMA (N  1,053)
Parameter 95% Confidence
Estimate Interval P Value
Whole-lung emphysema proportion (950 HU)
Intercept 0.270 (0.197, 0.341)  0.0001
FEV1, % predicted 0.0008 (0.0018, 0.0003) 0.16
Age, yr 0.001 (0.0021, 0.00006) 0.06
Pack-years 0.0003 (0.0005, 0.00007) 0.01
Female sex 0.164 (0.305, 0.002) 0.02
Whole-lung emphysema proportion (910 HU)
Intercept 0.564 (0.483, 0.645)  0.0001
FEV1, % predicted 0.0025 (0.004, 0.001)  0.0001
Age, yr 0.0007 (0.002, 0.0005) 0.28
Pack-years 0.0004 (0.0006, 0.0001) 0.004
Female sex 0.030 (0.046, 0.014) 0.0002
Whole-lung alpha (950 HU)
Intercept 0.87 (0.73, 1.01)  0.0001
FEV1, % predicted 0.0001 (0.002, 0.002) 0.96
Age, yr 0.002 (0.0005, 0.004) 0.14
Pack-years 0.0005 (0.0001, 0.001) 0.02
Female sex 0.06 (0.03, 0.08)  0.0001
Whole-lung alpha (910 HU)
Intercept 0.60 (0.52, 0.69)  0.0001
FEV1, % predicted 0.002 (0.0006, 0.003) 0.004
Age, yr 0.0006 (0.0007, 0.002) 0.36
Pack-years 0.0003 (0.00007, 0.0006) 0.01
Female sex 0.02 (0.006, 0.04) 0.009
Definition of abbreviation: HU  Hounsfield Unit.
multidimensional index (36), the mBODE (17), we also found
that women exhibited higher scores than men. Extending these
findings using state-of-the-art quantitative CT imaging and histo-
logical techniques, our results lay the groundwork to integrate
248 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 176 2007
TABLE 4. HISTOLOGICAL FINDINGS IN MEN AND WOMEN
WHO UNDERWENT VOLUME REDUCTION SURGERY IN
THE NETT (N  101)
Males Females
Mean (SD) Mean (SD) P Value
Number 59 42
Age, yr 65.2  6.4 66.3  5.7 0.458
FEV1, % predicted 24.5  6.7 29.7  7.0 0.001
Pack-years 71.7  29.9 54.4  19.8 0.003
Pi, mm* 2.63 (1.26) 2.37 (1.33) 0.026
Total wall area, mm2 0.433 (0.301) 0.379 (0.327) 0.090
Total wall area/Pi* 0.256 (0.066) 0.267 (0.072) 0.040
Epithelium/Pi* 0.119 (0.026) 0.122 (0.031) 0.052
Muscle/Pi* 0.096 (0.029) 0.094 (0.029) 0.530
Lamina propria /Pi* 0.100 (0.034) 0.098 (0.031) 0.929
Adventitia/Pi* 0.175 (0.059) 0.190 (0.064) 0.004
* Expressed as square root of tissue area divided by the length of the basement
membrane (Pi).
population-based COPD research with current concepts on the
neuropsychological responses to stress and the molecular patho-
genesis of inflammation.
Sex-specific Parenchymal and Airway Abnormalities in
Relation to Airflow Limitation
The significant differences in the amount and distribution of
emphysema in women compared with men are novel findings
that encompass both severe ( 950 HU) and less severe
(910HU) emphysema. Few studies have examined the sever-
ity or distribution of emphysema in women with severe COPD.
In a population-based study, patients with clinically defined em-
physema were primarily male, whereas patients with chronic
asthmatic bronchitis were predominantly female (37). Using
state-of-the-art CT imaging, we confirm that emphysema is less
severe in women, especially distally, and when present, is charac-
terized by smaller hole size. Although the absolute differences
between the sexes were modest, all analyses were remarkably
consistent in their direction. Furthermore, in multivariate analy-
sis adjusting for FEV1, IC/TLC, mBODE, smoking history, and
age, the proportion of severe emphysema was significantly lower
in women, suggesting distinct differences in emphysema severity
and distribution.
Whether comparable degrees of cigarette smoking induce
greater reductions in lung function in female smokers is contro-
versial, with data for (6, 26, 38–40) and against (41–43) that
premise. Based on the ability to adjust for the proportion of
emphysema, we noted a higher FEV1% predicted in women at
a given duration of cigarette smoking, and no significant interac-
tion between sex and smoking history. Women in our cohort
initiated smoking at a later age than men. Given their lower
mean age at the time of randomization, these changes are consis-
tent with those reported by other investigators (http://www.
cdc.gov/tobacco/sgr/sgr_forwomen/pdfs/chp2.pdf), and may ex-
plain the lesser total pack-years of cigarette smoke exposure.
Because our patients were selected for severe chronic airflow
obstruction and an emphysematous phenotype, our data do not
exclude the possibility that lung function deteriorates faster in
female smokers during earlier stages of COPD (6, 26, 38–40, 44,
45). We noted a lower DlCO in women despite lesser anatomic
emphysema. This finding may relate to the complex contribu-
tions of lung mechanics and gas exchange which contribute to
DlCO. Interestingly, previous studies have identified a differential
impact of central relative to distal emphysema on DlCO (46).
Thus, differences in emphysema distribution identified in women
in the current study may help explain the differences in DlCO.
The similarity between the sexes seen in FEV1% predicted
implies that women should have a greater degree of peripheral
airway pathology (20). Indeed, using validated morphometric
techniques to analyze airway histology in a subset of our patients
with similar airflow obstruction and smoking history to the entire
cohort, we confirm that women have smaller airway lumens and
disproportionately thicker airway walls than men. This change
would be anticipated to alter airway compliance and increase
airways resistance. Theoretical analysis of the effect of airway
wall thickness on resistance indicates that in proportion to the
change in lumen radius even a minor thickening of the airway
wall amplifies the effect of muscle shortening on lumen caliber
and increases resistance of the airways (47).
Sex Differences in Health Status and Depression in
Advanced COPD
Women in our study had worse health status, reflected in a lower
QWB, although SF-36 PCS and SGRQ scores were similar in
both sexes. These data are congruent with the limited data on
sex differences in health status in COPD (48), which found that
women expressed greater dissatisfaction with their lives (49),
and were more likely to categorize their global self-reported
health as “not very well” than as “well” (30). Recently, a small
case control study suggested worse SGRQ in women (33), al-
though this finding was not supported by others (34, 50). Women
might report greater respiratory symptoms and worse health
status because they perceive a given physiological perturbation
differently (51).
Women in our study exhibited greater depression and signifi-
cantly worse SF-36 MCS scores. In addition, age and sex inter-
acted, with younger women exhibiting significantly greater Beck
and lower SF-36 MCS scores than older women; this trend was
much less evident in males. The magnitude of the difference in
multivariate modeling is within the range identified for mild
depression (15). Sex differences in depressive symptoms have
recently been reported in COPD (34, 52). Furthermore, depres-
sion may potentiate the sensation of breathlessness (34, 53).
Similar interactions between age and sex on depression have
been reported previously in healthy subjects (54). Several expla-
nations have been proposed for age and sex differences in de-
pression, including differences in defensiveness and rumination,
respectively (54). Older adults exhibit greater defensiveness (55)
and an increased ability to regulate emotions (56). Importantly,
women show greater defensiveness than men with increasing
age. Rumination is associated with increased depression, is more
common in women, and among women is inversely related to
age (57). Younger women’s tendencies to feel less control over
emotions and negative events, and feel a greater responsibility
for the emotional tone of relationships,maymediate the relation-
ship between rumination and depression (58). However, in an-
other recent study (59) rumination and depression were posi-
tively associated with peripheral blood lymphocyte, leukocyte,
and B cell counts, as well as health care utilization, in healthy
older adults but not in younger adults. Our data cannot provide a
mechanistic explanation for the reported differences, but suggest
that additional investigation in this area is required.
Potential Sex-specific Differences in Smaller Airways
and Parenchyma
Why cigarette smoking differentially affects the airways and
lung parenchyma of men versus women is unclear. Potential
explanations include greater baseline airway hyperresponsive-
ness in women (5, 60–62) and differences in particulate deposi-
tion within the airways (2, 4). The magnitude and character of
the inflammatory response to cigarette smoke is likely to be
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affected by sex hormones, for which several leukocyte subsets
have receptors. Progesterone induces cyclical changes in IL-8
production (63) and promotes a Th2 cytokine response (64).
Cyclical changes in estradiol concentrations in women have been
associated with changes in lung adrenergic receptor density and
in concentrations of mucus, acetylcholine, and prostaglandin (4).
Estradiol also increases T cell expression of receptors for CC
chemokines and alters T cell homing patterns (65). Interestingly,
analysis of bronchoalveolar fluid in healthy individuals showed
a significantly increased percentage of CD4 T cells in women
over age 43, compared with men and with younger women (66).
Idiopathic cough, associated with lymphocytic inflammation
manifest as bronchoalveolar lymphocytosis, is seen predomi-
nately in olderwomen (67). However, even though human innate
and adaptive immune responses show complex degrees of sexual
dimorphism that vary with the specific pathogen and over the
life of the individual (68), current understandings of this dimor-
phism do not fully explain sex-based differences in COPDpatho-
genesis or phenotype, and most importantly, do not yet suggest
opportunities for prevention or treatment.
Limitations of this study come from its highly selective sample
population. All subjects were enrolled in NETT, a randomized
trial of lung volume reduction surgery for patients with a pre-
dominantly emphysematous phenotype. As such, selection bias
was imposed by requirements for sustained smoking cessation
and absence of comorbidities or significant sputum production.
Similarly, the requirement for severe emphysema limits general-
izability to all patients with COPD, as does the potential of a
referral bias varying by sex. On the other hand, no specific sex-
related factors were included in the evaluation process or in the
inclusion/exclusion criteria, which should minimize bias in the
current analyses. The cross-sectional nature of the analyses also
limits the ability to define mechanisms and distinct phenotypes.
Nevertheless, the results of our study should be considered as
hypothesis generating. It is possible that our findings on emphy-
sema characteristics and airway abnormalities result principally
from the greater size of the adult male lung. Importantly, sex
differences in emphysema distribution and proportion persisted
after extensive analyses adjusting for lung volume.
In summary, this study shows that women with severe COPD
exhibit distinct disease manifestations than men. Relative to
men, advanced COPD in women is characterized anatomically
by smaller airway lumens and disproportionately thick airway
walls, and by emphysema that is less extensive, manifest by
smaller hole size and less peripheral involvement. These ana-
tomic differences are accompanied by distinctive symptomatol-
ogy. At a given FEV1%predicted, age, and proportion of emphy-
sema, female patients with COPD report greater breathlessness
and depression, despite similar health status. Our data should
motivate future studies to determine the complex interactions
between biological and sociocultural factors (4) that contribute
to these differences, and thus to provide a foundation for novel
therapies to reduce the increasingly disproportionate burden of
this common disease in women.
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